

Sensitivity of 3D7 and W2 Clones in a Formulated Transport Medium and EDTA Anticoagulants against a Panel of Antimalarials

Scolastica C. Korir¹ Rose M. Kakai¹ Hosea M. Akala²

1. Department of Medical Microbiology, Maseno University, P.O. Box Private Bag, Maseno.

2. Kenya Medical Research Institute, Malaria Drug Unit, Kisumu

Abstract

Introduction: *in vitro* drug sensitivity relies on the growth of plasmodium in the presence of the antimalarials. These fresh isolates brought in for assay from collection sites normally not near the laboratory require a medium to keep the parasites viable in order to produce results which are a representation of the field situation in terms of drug susceptibility. Since factors such as mixed infection of drug resistant and sensitive parasites occurring in most field isolates can influence drug test outcome because they have different drug susceptibilities, **Method:** This study validated the use of a formulated transport medium (TM) by assaying clones which have been culture adapted in the lab for 50% inhibitory concentrations (IC₅₀) against four antimalarials using SYBR Green 1 *in vitro* assay. These clones (3D7 and W2) were revived and recultured for assay. Prior to subjecting them to drugs, they were exposed to 2ml formulated TM and the conventional EDTA anticoagulant in 5ml vacutainer tubes to act as control. **Results:** Similarity was detected with no significant difference ($P > 0.05$) observed in the medians inhibitory concentration 50 (IC₅₀) between samples in the EDTA anticoagulant and TM holds however, samples in EDTA generally had higher IC₅₀ values. **Conclusion:** This study concludes that the formulated TM holds promise for future use,

Keywords: clones, transport medium, EDTA, susceptibility, inhibitory concentration 50, isolates

Introduction

In Kenya Malaria is still the leading cause of morbidity and mortality (Kenya Ministry of Public Health and Sanitation, 2009). The disease accounts for 30 percent of Kenya's outpatient visits, 19 percent of hospital admissions, two to three percent of inpatient deaths, and is a leading cause of death among children under the age of five (Kenya Ministry of Public Health and Sanitation 2011). Specifically, in Western Kenya, 32% of all deaths are associated with Malaria, It causes 22% deaths among children with severe malaria, out of which 10% occur in hospitals and 13% outside hospitals within 8 weeks after admission. Also, treatment of malaria with chloroquine in the region was associated with 33% case fatality rate compared to 11% for children treated with more effective regime (Jane *et al.*, 1996). A variety of drugs have been used to treat malaria in Kenya over the years, including quinine and related compounds such as chloroquine, antifolate combination drugs, antibiotics, and artemisinin compounds. Efforts to control the spread of the disease, however, are hampered by a growing trend of resistance to antimalarial medications. This is a great concern to the Kenyan government, whose goal is to decrease morbidity and mortality due to malaria by 30 percent by 2017 (Kenya Ministry of Public Health and Sanitation 2011). It is predicted that clinical infections and death will begin to increase due to rapid spread of drug resistance parasites (Hastings and Alessandro, 2000).

In addition to resistance to antimalarial combination therapies, there is also a concern with *Plasmodium* mixed infections. A mixed infection is defined as an infection with more than one type of species or genotype of *Plasmodium* (Ferdig and Su, 2000). Other groups have noted that a number of malarial infections are heterogeneous in their composition (Lorenzetti *et al.*, 2008). Mixed infections of different genotypes are highly prevalent in malaria-endemic areas, particularly in Africa and Southeast Asia (Kobbe *et al.*, 2006). In fact, almost all infections occurring in nature are mixed. Although highly understudied, the implications of a mixed infection are profound. They can cause a relapse as a result of emergence of the resistant subpopulation of parasites after the sensitive subpopulation has been eradicated by drug therapy. The existence of a resistant population may be a result of both divergent evolution, where parasites have acquired resistance mechanisms, and/or two cohabitating parasites when the individual is infected (Hyde, 2002). This phenomenon has been observed in areas of malaria endemicity in Africa and Southeast Asia where the mixed-infection prevalence is as high as 30% (Mayxay *et al.*, 2004). However, there has been conflicting evidence as to the true frequency of *Plasmodium* mixed infections (Richie, 1988). Furthermore, this problem is confounded by the inability to properly identify and differentiate *Plasmodium* mixed infections. This phenomenon is possibly due to the assay's detection limit, where susceptibility of one population ceases to affect the profile of the other subpopulation, effectively masking the existence of that subpopulation. At this low parasite subpopulation level, dominance of a resistance mechanism may not be high enough in the population and may result in the appearance of only one phenotype. The reverse is also possible, where a large susceptible subpopulation may influence the apparent

phenotype of the whole population. Most naturally occurring malaria infections are composed of mixed subpopulations with different drug susceptibilities (Postigo *et al.*, 1998). It is likely that mixed infections of both drug sensitive and resistant parasites in a patient will produce test readings not representative of a typical resistant or sensitive parasite. Thus, there is a need of using clones which have identified these drug resistant subpopulations to prevent treatment failures, misidentification of a populations susceptibility profile (Zimmerman *et al.*, 2004) and also in any evaluation procedure so as to provide accurate test results.

Materials and methods

Ethical consideration

This study was approved by Jaramogi Oginga Odinga teaching and referral hospital Ethics and review committee (JOOTRH ERC).

Sample preparation

These are clones which were kept in liquid nitrogen and needed to be recultured for the experiment.

First the isolates were removed from liquid nitrogen and indicated in the nitrogen freezer log sheet, and then the vials were left to thaw in the incubator. Once the content liquefied it was transferred aseptically in to a 15ml centrifuge tube noting the volume. Slowly 1/5 volume of 12% solution NaCl was added while swirling the tube. It was allowed to stand at room temperature for 5 minutes. 9 volume of 1.6% NaCl solution was added to it and was centrifuged at 1500rpm for 3 minutes. Supernatant was aspirated before another 9 volume of 0.9% NaCl and 0.2% dextrose solution were added. This was mixed gently and centrifuged at 1500rpm for 3 min, and then supernatant was aspirated. It was resuspended in culture medium by adding 4.5ml of 10% complete medium and 0.5ml of washed Rbcs for a 5ml culture. Then the culture was gassed and placed in an incubator at 37°C to grow. Medium was being changed after every 48 hours while gassing the bottles. Parasitaemia was checked three times weekly until the parasitaemia was 3-8%. Once the clones were ready for assay they were subjected to EDTA and the formulated TM for at least 6 hours before they were washed in RPMI 1640 by centrifugation at 2500 revolutions per minute for 3 minutes for three consecutive times. samples with > 1% parasitemia were adjusted to 1% parasitemia at 2% hematocrit using uninfected O+ erythrocytes, and those with ≤ 1% parasitemia were used unadjusted at 2% hematocrit. Transfer of parasite sample and antimalarial drug aliquots in complete RPMI 1640 drug aliquots onto 96-well microculture plates and addition of lysis buffer after 72 hours incubation was done as previously described (Johnson *et al.*, 2007). The plates were then placed at room temperature in the dark, for 5–15 minutes. Parasite replication inhibition was quantified and the IC₅₀ for each drug calculated by an equation generating a sigmoidal concentration response curve (variable slope), with log transformed drug concentrations on the X axis and relative fluorescent units (RFUs) on the Y axis (Graphpad Prism for Windows, version 5.0; Graphpad Software, Inc., San Diego, CA). (Bacon *et al.*, 2007).

Results

Reference *Plasmodium falciparum* clones were assayed against the panel of antimalarials mentioned earlier. W2 considered as chloroquine resistant, mefloquine sensitive and artemisinin sensitive and 3D7 considered as chloroquine sensitive and mefloquine sensitive were used. Both clones gave successful assays in 95% of the plates in both EDTA and TM. Moderate RFU values of between 2000 to 4000 parasites were obtained by 3D7 clone while W2 had RFU values as high as 20,000 parasites. However, their curves converged into a discernible dose-response curve for IC₅₀ determinations with most/all of the points of the 10 standard dilutions included in the sigmoidal curve, for most of the plates and recording a reliability value (r²) of almost 1 (to be specific 0.9999) as shown in an example in figure 1 below. For W2 clone the IC₅₀ values in ng/ml for the samples in EDTA were all higher than their respective IC₅₀ values in TM as shown in table 1 below. The same table continues to show that there weren't any significant difference (P = 0.3697 and 0.2084) in IC₅₀ values in samples treated with LUM and DHA, but a high significant decrease (p < 0.001) in IC₅₀ values for samples subjected to ART and PPQ in TM was recorded. ART emerged to have the best activity with the least IC₅₀ values for samples in both EDTA and TM thus coinciding with the fact that W2 is artemisinin sensitive. On the other hand, LUM which is a recommended first line partner drug to ART in uncomplicated malarial treatment had the highest IC₅₀ values of 32.61 and 29.32 in EDTA and TM respectively. As seen in figure 2 below, samples in both categories had the lowest individual IC₅₀ of above 20ng/ml unlike other drugs whose minimum IC₅₀ values were as low as 0.106 for DHA.

Figure 1: Example of sigmoidal curves generated by clones indicating RFU values against the concentration of a drug.





Figure 2: *In vitro* distribution of W2 IC₅₀ values for samples in EDTA and TM

in vitro activity of W2 clone in EDTA and TM to antimalarials




The abbreviations E and T represent samples in EDTA and in Transport medium respectively. The medians IC₅₀ (purple bars) with their interquartile ranges in black for all the drugs

Table 1: Drug susceptibility testing of W2 reference clone in EDTA and TM against a panel of antimalarials

Median IC ₅₀ in ng/ml for W2 reference clone				
samples in EDTA		Samples in (Transport medium) TM		P values of the medians using Mann - whitney test (P)
	Drugs	Median	Median	
1	Artemether	3.118	1.873	<0.001
2	Lumefatrine	32.61	29.32	0.3697
3	Dihydroartemisinin	18.22	14.93	0.2084
4	Piperaquine	18.93	11.41	<0.001

Compared to W2, 3D7 clone showed reduced IC₅₀ values for all the antimalarials for samples in EDTA and TM except for ART (which had an IC₅₀ of 1.667 against 3.118 of W2). Besides, like W2, samples in EDTA had higher IC₅₀ values than samples in TM as shown in table 2. However there wasn't any significant difference (p=0.2549 and 0.3377) for samples exposed to ART and LUM in the two categories, while there was a high significant decrease (p=0.009 and 0.028) for samples in TM when they were treated with DHA and PPQ respectively. Repeatedly, ART remained the most active drug with the least IC₅₀ values while LUM retained its high IC₅₀ values. Notably, in both clones, PPQ is the only drug with a persistent significant difference in IC₅₀ values in the two anticoagulants. PPQ and ART have close IC₅₀ ranges between the minimum and the maximum values as shown in the figures 3 below.

Figure 3: *In vitro* distribution of 3D7 IC₅₀ values for samples in EDTA and TM



The abbreviations E and T represent samples in EDTA and in Transport medium respectively. The medians IC₅₀ (purple bars) with their interquartile ranges in black for all the drugs

Table 2: Drug susceptibility testing of 3D7 reference clone in EDTA and TM against a panel of antimalarials

Median IC ₅₀ in ng/ml for 3D7 reference clone				
samples in EDTA			Samples in (Transport medium) TM	P values of the medians using Mann - whitney test (P)
	Drugs	Median	Median	
1	Artemether	1.667	2.353	0.2549
2	Lumefantrine	22.27	9.905	0.3377
3	Dihydroartemisinin	2.853	10.03	0.0098
4	Piperaquine	7.181	13.0	0.028

Using Pearson's correlation coefficient, there was no correlation significance ($P > 0.05$) between the two anticoagulants as indicated by their r values shown in table 4 and 5 below. However no significant difference ($P > 0.05$) was observed between the individual activities of drugs as illustrated earlier in tables 3 and 4.

Table 3: Correlations between EDTA and TM: results for W2 reference clone

Sample in EDTA subjected to:	Samples in TM subjected to:	Correlation coefficient (r)	Probability P value
ART	ART	-0.0110	0.9611
LUM	LUM	-0.277	0.1901
DHA	DHA	-0.2577	0.2727
PPQ	PPQ	-0.1487	0.4983

Table 4: Correlations between EDTA and TM: results for 3D7 reference clone

Sample in EDTA subjected to:	Samples in TM subjected to:	Correlation coefficient (r)	Probability P value
ART	ART	0.03275	0.8765
LUM	LUM	0.156	0.4771
DHA	DHA	-0.021	0.9297
PPQ	PPQ	-0.3025	0.1416

The correlation coefficient was calculated by Pearson's correlation coefficient of log IC₅₀ values. Probability refers to the significance level of the test ($p < 0.05$). ART- Artemether, LUM - Lumefantrine, DHA - Dihydroartemisinin and PPQ – Piperaquine

Discussion

Among the assays of the reference clones, in both anticoagulants, the IC₅₀ range between the individual minimum and maximum values were small, this reflects reduced biological variability due to the absence of resistant and sensitive subpopulations of parasites, therefore, they were able to produce distinct IC₅₀ dose response curves with most points of the standard dilutions include in the sigmoidal curve. This is in accordance with a study which argued that a pure parasite population either resistant or sensitive to a drug, will produce a curve with a sharp inhibition of parasite growth at a relatively narrow range of drug concentration, whereas a

mixed population with a minor resistant population of 10% or higher will produce a flattened curve or a double-hump curve, reflecting two parasite populations with different IC₅₀. (Liu *et al.*, 2008). Nonetheless, it has been reported that among the field isolates, most naturally occurring malaria infections are composed of mixed subpopulations with different drug susceptibilities (Postigo *et al.*, 1998, Zimmerman *et al.*, 2004) but a large susceptible or resistant subpopulation may influence the apparent phenotype of the whole population (Co-em *et al.*, 2009), a factor relevant to the current finding. On the other hand, W2 considered chloroquine resistant demonstrated an aspect of 'resistance' in all the drugs by having elevated IC₅₀ values in all the drugs except for ART since it is considered artemisinin sensitive.

The high significant decrease in the medians for the W2 samples exposed to ART and PPQ and also a slight significant difference for DHA and PPQ in the 3D7 samples would have been affected by the selection of subpopulations in a clinical sample during initial culturing and isolation of the clones, since it has been reported that when clinical strains are culture adapted, they result in possible loss of the minor subpopulation and consequent misidentification of the population's susceptibility profile (Basco and Lebras, 1994, Basco and Lebras, 1990). Also in line with a finding which was concerned that during culture adaptation there could be selection of a dominant clone (Liu *et al.*, 2008). Anyway, other studies have also shown that even with culture adaptation, the minor subpopulation is still detectable (Mbaisi *et al.*, 2004). Additionally, the PPQ activities of 3D7 and W2 in both anticoagulants obtained in the current study were in line with the PPQ activities of 8.3 and 16 ng/ml in chloroquine sensitive and chloroquine resistant clones obtained by Vennerstrom *et al.*, 1992. It was further observed that PPQ and LUM among the clones had the least activity, and this could have been attributed by the fact that the drugs are longer acting partner drugs to artemisinin derivatives with much longer half life, of 3-4 days and 3-4 weeks for LUM and PPQ respectively (German and Aweeka, 2008) thus, in subsequent infections they are exposed to subtherapeutic concentrations of these drugs, facilitating selection of parasites.

References

1. Basco, L. K., and J. Le Bras. 1990. Reversal of chloroquine resistance with desipramine in isolates of *Plasmodium falciparum* from Central and West Africa. *Trans. R. Soc. Trop. Med. Hyg.* 84:479–481.
2. Basco, L. K., and J. Le Bras. 1994. *In vitro* susceptibility of Cambodian isolates of *Plasmodium falciparum* to halofantrine, pyronaridine, and artemisinin derivatives. *Ann. Trop. Med. Parasitol.* 88:137–144.
3. CoEM, Denuall, R. A., Reinbold, D. D., Waters, N. C., & Johnson, J. D. (2009). Assessment of malaria *in vitro* drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay. *Antimicrobial Agents Chemotherapy*, 53, 2557-2563.
4. Hastings, I. M., & Alessandro, U. D. (2000). Modelling a predictable disaster: the rise and spread of drug-resistant malaria. *Parasitology Today*, 16, 340-347.
5. Hyde, J. E. (2002). Mechanisms of resistance of *Plasmodium falciparum* to antimalarial drugs. *Microbes and Infection*, 4, 165-174.
6. Jane, R. Z., Eve, M. L., Trenton, K. R., Allen, W. H., John E., Ben O. W., Beverly M., Ellen, P., and Carlos, C., (1996). Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. *American Journal of tropical Medicine and hygiene*, 55 (6), 655-660
7. Kenya Ministry of Public Health and Sanitation, M. P. H. S. (2011). "Kenya Malaria Fact Sheet." Nairobi.
8. Kenya Ministry of Public Health and Sanitation, M. P. H. S. (2009). National Malaria Strategy 2009–2017. Nairobi.
9. Kobbe, R., Neuhoﬀ, R., Marks, F., Adjei, S., Langefeld, I., von Reden, C., Adjei, O., Meyer, C.G., May, J. (2006). Seasonal variation and high multiplicity of first *Plasmodium falciparum* infections in children from a holoendemic area in Ghana, West Africa. *Trop Med Int Health* 11: 613–619.
10. Liu, S., J. Mu, H. Jiang, and X.-Z. Su. 2008. Effects of *Plasmodium falciparum* mixed infections on *in vitro* antimalarial drug tests and genotyping. *Am. J. Trop. Med. Hyg.* 79:178–184.
11. Lorenzetti, A., P. A. Fornazari, A. C. Bonini-Domingos, R. D. S. R. Penhal-bel, E' . Fugikaha, C. R. Bonini-Domingos, V. D. Fraga, L. M. Concei,caõ, A. R. B. Rossit, C. E. Cavasini, V. S. C. D. Couto, and R. L. D. Machado. (2008). Mixed *Plasmodium faciparum* infections and its clinical implications in four areas of the Brazilian Amazon region. *Acta Trop.* 107:8–12.
12. . Mayxay, M., S. Pukrittayakamee, P. N. Newton, and N. J. White. (2004). Mixed-species malaria infections in humans. *Trends Parasitol.* 20:233–240.
13. Mbaisi, A., P. Liyala, F. Eyase, R. Achilla, H. Akala, J. Wangui, J. Mwangi, F. Osuna, U. Alam, B. L. Smoak, J. M. Davis, D. E. Kyle, R. L. Coldren, C. Mason, and N. C. Waters. 2004. Drug susceptibility and genetic evaluation of *Plasmodium falciparum* isolates obtained in four distinct geographical regions of Kenya. *Antimicrob. Agents Chemother.* 48:3598–3601
14. Postigo, M., A. Mendoza-Leo´n, and H. A. P´erez. 1998. Malaria diagnosis by the polymerase chain reaction: a field study in south-eastern Venezuela. *Trans. R. Soc. Trop. Med. Hyg.* 92:509–511.
15. Richie, T. L. (1988). Interactions between malarial parasites infecting the same vertebrate host. *Parasitology*

- 96: 607–639.
16. Vennerstrom, J. L., W. Y. Ellis, A. L. Ager, S. L. Andersen, L. Gerena, and W. K. Milhous. (1992). Bisquinolines. 1 N, N-bis(7-chloroquinolin-4-yl) alkanediamines with potential against chloroquine-resistant malaria. *J. Med. Chem.* 35:2129–2134
 17. Zimmerman, P. A., R. K. Mehlotra, L. J. Kasehagen, and J. W. Kazura. 2004. Why do we need to know more about mixed *Plasmodium* species infections in humans? *Trends Parasitol.* 20:440–447